Kornimate/medical-research-clean huggingface dataset:
social network approach for increasing testing coverage among men who have sex with men

Conditions: HIV Infections

Summary: hiv testing is essential in shortening the time to identify a new infection, the first 90 of the unaids 90-90-90 targets. however, over one-third of the men who have sex with men (msm) had never been tested for hiv; even if they did, one-fifth had their tests done more than a year ago. assortative mixing pattern observed in the hiv-positive msm group shaped the transmission dynamics and could be leveraged for intervention. barriers to access hiv testing services could, on the other hand, be hurdled by self-tests. a network approach for intervention could therefore be promising in delivering effective hiv self-tests. to experiment with such an approach, a 2-phase study was conceptualised incorporating actual network-based referred hiv self-tests and an agent-based simulation evaluating its impact. sixty-four msm would be recruited as seeds for promoting hiv self-tests within their network and those being referred could refer their friends for the same after passing online training. to facilitate the process, an online platform would be developed offering information, collecting informed consent, requesting hiv self-test kits, returning results, performing online training, and referring peers. participants could opt to receive self-tests by delivery or to conduct it on-site with staff assistance. a hotline with video conferencing support would be maintained to assist those who self-test at home. they could also choose between blood and oral fluid tests. two user interfaces, namely gamification and neumorphism, would be randomly assigned. primary outcomes to measure are number and proportion of msm who had never or not tested within 12 months and the associating factors, and usability of the two user interfaces. data collected in the empirical study would be used for parameterising the agent-based simulation to evaluate the impact of the approach in increasing testing coverage and shortening time to diagnosis. its economic assessment would also be performed to cost each new infection to be identified. the approach could be feasible and effective to be adopted for future broader implementation for peer-led hiv self-test kit or hiv prevention message distribution.


Eligibility criteria:
inclusion criteria: * male * had sex with another male in the preceding year * able to communicate in written chinese or english * normally resided in hong kong exclusion criteria: * prisoners * having mental illnesses that informed consent cannot be obtained

Keywords: men who have sex with men self-testing social network agent-based model hiv gamification neumorphism
clinical investigation of new ci delivery models in an adult nucleus ci population

Conditions: Sensorineural Hearing Loss, Bilateral; Cochlear Implant

Summary: use of artificial intelligent (ai) technology to assist audiologists in programming cochlear implants.


Eligibility criteria:
inclusion criteria: newly implanted and existing recipient groups (groups 1 and 2): * age 12 and older * monosyllabic word score administered at 60dba (2 lists) with an appropriately fit hearing aid in the ear to be implanted who are receiving a cochlear implant as standard of care * group 2: 3 months or greater combined experience with commercially available sound processors * fluent spoken english skills exclusion criteria: * unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations * additional cognitive, medical or social handicaps that would prevent completion of all study requirements as determined by the investigational team * unwillingness or inability of the subject to comply with all investigational requirements * use of an acoustic component in the implanted ear * less than 18 active electrodes * hybrid l cochlear implant
short and long-term effects of adding oral l-arginine to standard therapy in patients with covid-19 (sars-cov-2)

Conditions: Covid19

Summary: single-center study with a parallel group scheme, double-blind, randomized, placebo-controlled, to evaluate whether the addition to the investigator's hospital standard therapy of two vials of bioarginina® per day in subjects with sars-cov-2 is useful for treatment of this pathology.

preliminary experiences conducted in patients affected by sars-cov-2 infection by adding the daily oral administration of two vials of bioarginina® to the standard therapy have shown favorable effects on discharge times, on the recovery of the number of lymphocytes and on the p \\ f ratio between arterial po2 and fio2 breathed. in particular, for the latter parameter there is almost a doubling of the recovery speed. the investigators therefore, decided to undertake the present spontaneous, single-center study with a parallel group scheme, double-blind randomized, placebo-controlled to evaluate whether the addition to the standard therapy of two vials per day of bioarginina® in subjects of our hospital suffering from sars-cov-2 is useful for the treatment of this pathology.

Eligibility criteria:
inclusion criteria: * age\> 18 years * diagnosis of covid 19, confirmed by rt-pcr on a nasopharyngeal swab * covid 19 pneumonia with the following clinical characteristics: spo2 in ambient air \<93% and alveolar pressure of oxygen / inspiratory fraction of oxygen (pao2 / fio2 - p / f \<300 mmhg. * lymphocytopenia defined as lymphocytes \<1500 / mcl or \<20% of white blood cells exclusion criteria: * history of intolerance to l-arginine * severe chronic pulmonary disease * pregnancy or breastfeeding * neutropenia due to neoplasms of the haematopoietic system or other organs with invasion of the bone marrow * use of immunosuppressive drugs or cytotoxic chemotherapies within the previous three weeks * refusal to give consent to participate in the study
nutritional supplements for exercise recovery

Conditions: Post-exercise Muscle Soreness

Summary: this study will examine the effects of nutritional supplement on post-exercise muscle soreness as well as recovery of muscle strength and function.


Eligibility criteria:
inclusion criteria: * ability to consume supplement * willing to adhere to the study intervention regimen * willing to abstain from analgesics for duration of the study * agreement to adhere to lifestyle considerations exclusion criteria: * current use of nsaids * use of other nutritional or herbal supplements (e.g., protein powders, tart cherry juice, bcaas, vitamin d, probiotics, etc.) that have been shown to effect primary or secondary outcomes * presence of chronic diseases, including, but not limited to, cancer, hiv, hepatitis, cardiovascular, metabolic, and orthopedic conditions * weight \> 350 pounds * pregnancy or lactation * known food allergies or sensitivities or dietary restrictions * habitual consumption of \> 2 alcoholic drinks per day * febrile illness or antibiotic use within 1 month prior to baseline testing * treatment with another investigational drug or other intervention within 1 month * current smoker or tobacco use within 1 month * any condition(s) or diagnosis, both physical or psychological, that, in the opinion of the principal investigator or study physician, precludes participation and/or ability to consent * any other factor that, in the opinion of the principal investigator or study physician, would cause harm or increased risk to the participant or close contacts, or preclude the participant's full adherence with or completion of the study
physical,histological,and genetic analyses of lipid-rich atherosclerotic plaques

Conditions: Atherosclerosis; Aortic Aneurysm; Peripheral Vascular Diseases

Summary: lipid-rich atherosclerotic plaques, or "vulnerable plaques" are prone to rupture, causing local intravascular thrombosis, with subsequent grave clinical consequences. atherosclerotic plaques normally removed during surgery, and peripheral blood samples will be studied to achieve the following objectives: "1" define histological features of the vulnerable plaque, analyze its physical characteristics, and investigate selected gene expression. "2" study biomarkers of inflammation in conjunction with the presence of vulnerable plaques. "3" explore the potential role of infection in atherogenesis.


Eligibility criteria:
inclusion criteria: * evidence of symptomatic carotid stenosis exceeding 60%(tias or stroke within the last 6 months), and asymptomatic carotid artery stenosis (presenting with progressive carotid stenosis, exceeding 70%) * abdominal aortic aneurysm, and aortic occlusive disease * peripheral occlusive or aneurysmal disease exclusion criteria: * non-compliant patients, incapable of granting approval by informed consent

Keywords: atherosclerosis carotid plaque abdominal aortic aneurysm vulnerable plaque angiogenesis intraplaque hemorrhage carotid artery atherosclerosis
multicenter trial of immunologic markers to predict long term virologic outcomes

Conditions: HIV Infections

Summary: purpose is to identify whether immune markerscan predict success of salvage anti-retroviral therapy.

over the last several years two markers of disease have been utilized to determine if antiretroviral therapy has been successful, one is a cd4 cell count (reflects the immunocompetence of an infected individual) and a hiv viral load (a blood test used to determine the amount of hiv in the infected individual). however in patients who fail their first line of therapythe likelihood of extended resuppressing viral replication with subsequent therapies may be as low as 25-50%. this information may take several months to determine the new therapies possible continuing success. it would be preferable to have additional markers that respond to therapies in the first several weeks to such therapies, therfore possibly offering patients alternate treatment earlier without potentiatinglong term side effects and possible further drug resistance.

Eligibility criteria:
inclusion criteria: * patient must be hiv infected * must be \&#8805;18 years old * must have been taking the same combination arv regimen (\&#8805;3 drugs) for at least 3 months. * must be experiencing virologic failure (viral load \&#8805;50 copies/ml on two occasions at least 2 weeks apart). * must be changed to a salvage antiretroviral regimen * patient has to have signed and dated a full infomred consent. exclusion criteria: * patient with any of the following abnormal laboratory test results in the previous 3 months: * hemaglobin \&lt;100 g/l * platelet count \&lt;20,000 cells/l * inr \&#8805;3.5 iu * ptt \&#8805;60 iu * patient with other significant underlying disease (non-hiv) that might impact immune markers ( eg. advanced liver disease, malignancy).

Keywords: hiv immune markers
studies of neurological paraneoplastic syndromes

Conditions: Paraneoplastic Neurologic Degenerations (PNDs)

Summary: this study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer. such patients with paraneoplastic neurologic degenerations(pnds) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. this study aims to better understand pnds by: * analyzing for autoantibodies in serum and cerebral spinal fluid * analyzing for antigen specificity and for antigens in cancer tissue * comparing pnd autoantibodies with those in cancer patients but no pnd * comparing pnd autoantibodies with those in pnd patients but no cancer * studying the immune performance of patients with pnds as this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Eligibility criteria:
inclusion criteria: * all adults are potentially eligible. exclusion criteria: * none.
comparison of aortic root dimension changes during cardiac cycle between the patients with and without aortic valve calcification using ecg-gated 64-slice and dual-source 256-slice computed tomography scanners: results of a multicenter study

Conditions: Aortic Valve Calcification

Summary: this study seeks to compare aortic dimension changes during cardiac cycle in patients with and without aortic valve calcification and to evaluate its correlation with aortic valve calcium score in former group.

the study population comprised 104 patients referred to three cardiac imaging centers for coronary multislice computed tomography, including 52 patients with aortic valve calcification as the study group and 52 subjects without evidence of calcification in their aortic valve, who served as a control group. data were reconstructed at each 10% of rr-interval during the cardiac cycle and reconstructed images at 30-35% and 70-75% of r-r intervals were obtained, representing systole and diastole, respectively. for diastolic phase, in most cases images at 70% were acquired. thereafter, acquired images were transferred to a single remote workstation for post-processing and subsequent off-line analysis.

Eligibility criteria:
inclusion criteria: - patients referring for multislice coronary computed tomography for any reason exclusion criteria: * arrhythmia * hypertrophic cardiomyopathy * aneurysm formation of ascending aorta * marfan's disease * ehlers-danlos syndrome * history of coronary artery bypass surgery * history of coronary stenting * aortic valve surgery * thoracic aorta surgery * aortic valve stenosis

Keywords: aortic annulus aortic calcification multislice computed tomography cardiac cycle
assessing circulating tumor cell as a biomarker for prostate cancer detection in patients with gray zone psa level

Conditions: Prostate Cancer

Summary: prostate cancer screening with psa is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml). we introduce a new circulating-tumor-cell (ctc) biomarker for detection of prostate cancer in patients in the psa "gray zone" level, with the clinically verified potential to substantially decrease the number of unnecessary prostate biopsies.


Eligibility criteria:
inclusion criteria: * subjects are willing to sign the informed consent and agree to comply with the study procedures. * age from 20 to 99 years old * subjects with a psa 4.00- 10.99 ng/ml and will receive biopsy within 3 months exclusion criteria: * age \< 20 years * refuse to sign the informed consent form * received regional anesthesia and general anesthesia within one month * previous cancer history * autoimmune diseases * chronic inflammatory diseases * diagnosed with colorectal polyps or adenomas * acute inflammatory or infectious diseases in three months * other diseases decided by pi
study of split-course chemoradiotherapy for locally advanced none-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this phase ii study is to determine the efficacy of split-course irradiation with concurrent chemotherapy in locally advanced none-small cell lung cancer patients.

this phase ii study is to determine the efficacy of split-course chemoradiotherapy(ccrt) in locally advanced non-small cell lung cancer. patients receive four cycles of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, combined with split-course thoracic radiotherapy of 51 gy/17 fractions and 15-18 gy/5-6 fractions administered in the first and second courses, respectively, with about one-month break. the primary endpoint is progression-free survival, which is calculated from the start of rt to the first identification of disease progression or death. progression-free survival will be calculated using the kaplan-meier method. toxicities will be graded according to ctcae v.4.0.

Eligibility criteria:
inclusion criteria: * pathologic confirmation of nsclc. * patients have measurable or evaluable lesions based on the response evaluation criteria in solid tumors (recist) criteria. * unresectable phase iiia(n2) and iiib lung cancer confirmed by pet/ct, ct or mri. * eastern cooperative oncology group (ecog) performance status 0-1. * previously treated with chemotherapy or treatment-naive * no previous chest radiotherapy, immunotherapy or biotherapy * hemoglobin≥10 mg/dl, platelet≥100000/μl,absolute neutrophil count ≥1500/μl * serum creatinine ≤1.25 times the upper normal limit(unl), or creatinine clearance≥60 ml/min * bilirubin ≤1.5 times unl, ast（sgot）≤2.5 times unl ,alt（sgpt）≤2.5 times unl,alkaline phosphatase ≤5 times unl * fev1 \>0.8 l * cb6 within normal limits * patients and their family signed the informed consents exclusion criteria: * previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ * contraindication for chemotherapy * malignant pleural or pericardial effusion. * women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose * women who has the probability of pregnancy without contraception * tendency of hemorrhage * in other clinical trials within 30 days * addicted in drugs or alcohol, aids patients * uncontrollable seizure or psychotic patients without self-control ability * severe allergy or idiosyncrasy * not suitable for this study judged by researchers

Keywords: non-small cell lung cancer split-course chemoradiotherapy
to determine the efficacy of the twinguard in oxygen delivery during and post endoscopic procedure

Conditions: Hypoxia; Hypercapnia

Summary: a comparative study which compares the end-tidal carbon dioxide and oxygen saturation levels of patients during endoscopy which have used either the new oral-nasal oxygenating device (twinguard), or a standard bite block plus nasal cannulae using an equivalent flow rate of oxygen.

hypoxia is common during endoscopy. following sedation induction, oxygen saturation falls moderately in most patients, whilst some drop to unacceptable levels. to monitor such changes endoscopic practices routinely use oximeters and capnography. twinguard is an all-in-one device which incorporates a bite block with the functionality of nasal cannula as well as monitoring expired air (carbon dioxide)

Eligibility criteria:
inclusion criteria: * provided written fully informed consent as per protocol * no clinical evidence of significant respiratory conditions * fasted for 6 hours prior to enrolment as per standard clinical practice for panendoscopy exclusion criteria: * patients suffering from cardio respiratory disease, moderate to severe asthma, lung and heart disease * patients who have a history of drug or alcohol abuse

Keywords: prevention of hypoxia prevention of hypercapnia
validation of a nutrition screening tool

Conditions: Malnutrition

Summary: the purpose of this study is to compare the accuracy of a new consumer nutrition screening tool to an established and validated nutrition screening tool currently completed by healthcare practitioners.

the main objective of the study is to determine the accuracy of the self-administered consumer mini nutritional assessment by comparing the level of agreement in the categorization of nutritional status between the self-administered mini nutritional assessment and a validated nutrition screening tool in a population aged 65 and older.

Eligibility criteria:
inclusion criteria: - consumer * age ≥ 65 years * employed part-time, unemployed, retired, full-time homemaker * english speaking - caregiver of consumer * family, relative, friend, professional caregiver of an individual age ≥ 65 years * lives with individual aged ≥ 65 years or visits individual aged ≥ 65 years five or more days a week * makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs. * english speaking exclusion criteria: - consumer -- full time employment

Keywords: malnutrition nutrition status elderly nutrition screening
a longitudinal study looking at the prevalence, risk factors & consequences of persistent post-surgical pain in children

Conditions: Chronic Pain

Summary: the purpose of this study is to investigate the prevalence, risk factors and consequences of chronic post-surgical pain in children aged 0-16 years through a number of questionnaires completed at various timepoints, from before surgery up to 1 year post surgery.

the popsicle study is a multi-centre, international research study that will investigate the prevalence, risk factors and consequences of chronic post-surgical pain (cpsp) in children 0-16 years undergoing the following common paediatric surgeries: laparoscopic appendicectomy, scrotal exploration, orchidopexy, hypospadias repair and circumcisions. cpsp as well as risk factors and their association with chronic pain, including parent and child anxiety, pre-existing pain, peri-operative pain experience and acute post-operative management, will be assessed through a series of longitudinal questionnaires at 6 timepoints from pre-surgery to 10-12 months post-surgery. baseline measures will be completed pre-operatively and post-surgery measures of pain and function will be undertaken at day 2, 3-4 weeks, 3-4 months and 10-12 months post-operatively. chronic pain has a significant effect on children's quality of life, negatively impacting their physical, emotional and social health as well as schooling. additionally, adolescent chronic pain is associated with higher rates of depression, anxiety, feeling of helplessness and lack of autonomy compared to healthy children. therefore, evidence-based knowledge from this research will inform perioperative practice minimising the risk of a child going on to develop chronic post-surgical pain. this will benefit the child, their family and the healthcare system by aiding in the formulation of practice guidelines to follow high risk children more closely to treat any potential persistent pain earlier to avoid the development of chronic pain.

Eligibility criteria:
inclusion criteria: the patient is undergoing a surgical procedure in either group elective (circumcision, hypospadias, orchidopexy, laparoscopic appendicectomy) or group emergency (laparoscopic appendicectomy, scrotal exploration) exclusion criteria: the parent and child have inadequate english language skills to understand the questionnaires children with significant/severe developmental or cognitive delay based on a formal diagnosis. families that are unable to complete the long-term follow up surveys.

Keywords: chronic pain post-operative pain paediatric surgery
relationship of endometrial cancer and serum soluble l1cam level

Conditions: Endometrium Cancer

Summary: the aim of this study is to evaluate the effect of serum soluble l1cam (sl1cam) on the diagnosis and prognosis of endometrial cancer. this prospective randomized controlled trial will be conducted in patients who have undergone endometrial biopsy and whose pathology results are reported as benign endometrial changes, endometrial hyperplasia, or endometrial cancer. the sl1cam level between groups will be compared. the relationship between prognostic factors and serum sl1cam will be evaluated in patients with endometrial cancer.


Eligibility criteria:
inclusion criteria: * patients who underwent endometrial biopsy due to abnormal uterine bleeding and whose pathology results were reported as benign endometrial changes, endometrial hyperplasia or endometrial cancer were included in the study. all patients participating in the study signed informed consent. exclusion criteria: * patients who did not have consent, received neoadjuvant therapy and who would not have surgery despite endometrial cancer were excluded from the study.